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Gregory L. Moneta, MD, Section EditorGenetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. N Engl J Med 2008;359:
1897-908.
Conclusion: Polymorphisms of the C-reactive protein (CRP) gene are
associated with increases in CRP levels but are not in themselves associated
with an increased risk of ischemic vascular disease.
Summary: It is well known that elevated plasma levels of CRP are
associated with an increased risk of ischemic cerebrovascular and ischemic
cardiac disease. What is unknown is whether CRP levels themselves contrib-
ute to causation of ischemic cerebrovascular or cardiac disease, or are merely
markers of the existence of ischemic cerebrovascular or cardiovascular dis-
ease. The CRP gene has genetic variations that increase levels of CRP to
different degrees and therefore can theoretically be used to assess the
consequences of lifelong high CRP levels independent of additional risk
factors. The authors of this study sought to determine whether genetically
elevated CRP levels caused an increased risk of ischemic heart disease and
ischemic cerebrovascular disease.
The study included 10,276 people from a general population cohort.
Ischemic heart disease developed in 1786, and ischemic cerebrovascular
disease developed in 741. In an additional cohort of 31,992 persons from
the general population, 2521 had ischemic heart disease and 1483 had
ischemic cerebrovascular disease. The authors also studied an additional
2238 patients with ischemic heart disease and 4474 control participants
along with 612 patients with ischemic cerebrovascular disease and an addi-
tional 1224 control participants. High-sensitivity CRP was measured, fol-
lowed with genotyping of four CRP polymorphisms and two apolipoprotein
E polymorphisms.
In persons with CRP levels3 mg/L, compared with those with CRP
levels 1 mg/L, ischemic heart disease was increased by a factor of 1.6 and
ischemic cerebrovascular disease was increased by a factor of 1.3. The four
CRP polymorphisms resulted in an increase in CRP levels of up to 64%.
Theoretically, this would predict an increased risk of 32% for ischemic heart
disease and 25% for ischemic cerebrovascular disease. However, no genotype
combination was associated with an increased risk of either ischemic cere-
brovascular or ischemic cardiac disease. Apolipoprotein E genotypes were
associated with an increased risk of ischemic heart disease and elevated
cholesterol levels.
Comment: Drugs are being developed to specifically target lowering
CRP levels (Curr Atheroscler Rep 2006;8:421-8). The ultimate goal would
be to lower CRP levels and, if CRP is associated with causing atherosclerosis,
ultimately prevent the development of vascular disease. This study suggests
that such a strategy is likely to be “barking up the wrong tree.” Although
epidemiologic studies have observed an increased risk of ischemic vascular
disease associated with higher plasma CRP levels, the current data indicate
that increased CRP levels are perhaps more a marker for atherosclerosis than
a cause of atherosclerosis. Please see also the abstract for a related article
(N Engl J Med 2008;359:2195-207).
Rosuvastatin to Prevent Vascular Events in Men and Women with
Elevated C-Reactive Protein
Ridker, PM, Danielson E, Fonseca FAH, and the JUPITER Study Group. N
Engl J Med 2008;359:2195-207.
Conclusions: In patients with elevated high-sensitivity C-reactive pro-
tein (CRP) levels, who are otherwise apparently healthy without hyperlipid-
emia, rosuvastatin significantly reduced major cardiovascular events.
Summary: Increased levels of CRP, an inflammatory biomarker, pre-
dict cardiovascular events. Statin medications have been known to lower
cholesterol and levels of high-sensitivity CRP. The authors hypothesized
that patients with elevated high-sensitivity CRP levels, but with normal lipid
levels, might benefit from statin treatment. This was a randomized prospec-
tive clinical trial comprising 17,802 apparently healthy women andmenwith
low-density lipoprotein cholesterol (LDL-C) levels 130 mg/dL and with
high-sensitivity CRP levels 2.0 mg/dL. Patients were randomly assigned
to rosuvastatin (20 mg daily) or placebo. They were then monitored for the
occurrence of the primary end point of myocardial infarction, arterial revas-
cularization, hospitalization for unstable angina, stroke, or death from
cardiovascular causes.
After a median of 1.9 years of follow-up, the trial was stopped by the
safety monitoring committee. LDL-C levels were reduced by rosuvastatin by
50% and high-sensitivity C-reactive protein levels were reduced by 37%. The
rates of the primary end point were 0.77 and 1.36 per 100 patient-years of
follow-up in the rosuvastatin and placebo groups, respectively. Rosuvastatin
had a hazard ratio (HR) of 0.56 (95% confidence interval [CI], 0.46-0.69;
P  .00001). Rates for myocardial infarction were 0.17 and 0.37 per 100
534person-years in the rosuvastatin and placebo groups, respectively (HR, 0.46;
95% CI 0.30-0.70; P  .0002). For stroke, corresponding rates for 100
person-years were 0.18 and 0.34 for rosuvastatin and placebo groups (HR,
0.52; 95% CI 0.34-0.79; P  .002). Rates per 100 patient-years for
revascularization or unstable angina were 0.41 and 0.77 for the rosuvastatin
and placebo groups, respectively (HR, 0.53; 95% CI, 0.40-0.7; P 
.00001). For a combined end point of myocardial infarction, stroke, or
death from cardiovascular causes, the rates for rosuvastatin and placebo per
100 patient-years were 0.45 and 0.85, respectively (HR, 0.53; 95% CI
0.4-0.69; P  .00001). Finally, for death from any cause, rates for rosuvas-
tatin and placebo were 1.00 and 1.25 per 100 patient-years, respectively
(HR, 0.80; 95% CI, 0.67-0.97; P  .02). No significant increase in myop-
athy or cancer was noted in the rosuvastatin patients, but they did have a
higher incidence of diabetes.
Comment: The findings of this study are compatible with the now
well-accepted postulate that inflammation contributes to and is essential to
the atherosclerotic process. This study was stopped relatively soon after its
inception, and this raises the possibility that the events that occurred may be
independent of the usual mechanisms of progression of atherosclerotic
plaque. It does seem unusual that patients who have LDL-C levels that are
generally regarded as favorable would have marked progression of athero-
sclerosis in such a short time. The results may therefore indicate more of a
plaque stabilization effect of lowering CRP levels than inhibition of bulky
progression of existing plaque. The article should be examined in the context
of another article, also from the New England Journal of Medicine (N Engl
J Med 2008;359:1897-908), that is also abstracted in this issue of the
Journal of Vascular Surgery. This second article suggests that treatment of
CRP alone would be unlikely to be of benefit in patients at risk for
cardiovascular events. However, the two articles are not necessarily incom-
patible. It is reasonable to postulate that to derive benefit from treatment of
elevated CRP, it is also necessary to drive down the LDL-C level. Trials will
eventually be required with agents that can lower CRP—but not affect
cholesterol levels—to tease out the mechanism of benefit of rosuvastatin
therapy in patients with otherwise “acceptable” LDL-C levels and eleva-
ted CRP.
Anatomic Suitability of Ruptured Abdominal Aortic Aneurysms for
Endovascular Repair
Slater BJ, Harris EJ, Lee JT. Ann Vasc Surg 2008;22:716-22.
Conclusions: Only about half of patients with ruptured abdominal
aortic aneurysms (rAAAs) are candidates for endovascular aneurysm repair
(EVAR) with conventional stent graft devices.
Summary: Open surgical repair is the traditional strategy to treat
patients with rAAAs. The mortality rate is approximately 50%. There is now
considerable enthusiasm for EVAR of rAAAs. Small case series suggest
EVAR is feasible for rAAAs and may be associated with improved short-term
morbidity and mortality compared with open repair. Only one randomized
controlled study has compared open vs endovascular repair of rAAAs,
however, and it showed no difference in outcome (Eur J Vasc Endovasc Surg
2006;32:506-14).
The authors sought to investigate anatomic suitability of rAAAs for
EVAR by review of preoperative cross-sectional imaging. They retrospec-
tively analyzed a consecutive series of rAAAs. Imaging studies were used to
determine if EVAR could have been feasible based on available devices at the
time of data collection for the study. If the patients had an aortic neck
diameter 32 mm, a neck length 10 mm, neck angulation 60° severe
iliac tortuosity, or external iliac artery diameters6 mm, they were declared
noncandidates for EVAR.
During a 10-year period, 47 rAAAs were treated at this institution, of
which 60% were transferred from referring hospitals and 47% had free
rupture. During the past 2 years, five (11%) had been treated with EVAR,
and the remaining 42 patients underwent open repair. Preoperative imaging
was available in 43 of the 47 patients treated. Morphologic measurements
based on the criteria noted above indicated 49% would have been candidates
for EVAR. EVAR was precluded by inadequate neck length in 73%, unsuit-
able iliac access in 23%, large neck diameter in 18%, and severe angulation of
the aneurysm neck in 14%. The 30-day operative mortality rate was 34%, and
1-year mortality was 42%. EVAR candidates were more likely to be men
(95% vs 68%, P  .046), to have smaller sac diameters (7.0 vs 8.5 cm, P 
.0.2), and longer length necks (24.1 vs 8.6 mm, P .0001). They were also
less likely to have 60° angulated neck (10% vs 45%, P  .0002) and more
likely to have larger external iliac artery diameters (8.9 vs 7.3mm, P .015).
Comment: The results of this study, using a retrospective analysis of
cases up to 10 years ago, would seem to be relatively applicable to the
anatomy of patients currently with rAAAs. Anatomy of rAAAs is unlikely to
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be a viable alternative to open repair for patients with rAAAs. Such factors
include available surgical expertise, available nursing expertise, and of
course, available devices at all times in the operating room. It seems unlikely,
unless an institution has large exposure to patients with rAAAs, that all of
these things would come together with sufficient frequency that EVAR
repair of rAAAs will exceed open repair of rAAAs in the near future.
Effects of Extended-Release Metoprolol Succinate in Patients Under-
going Non-Cardiac Surgery (POISE Trial): A Randomized Controlled
Trial
POISE Study Group. Lancet 2008;371:1839-47.
Conclusion: The use of perioperative -blockade in patients undergo-
ing noncardiac surgery results in a decrease in the composite end point of
cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac
arrest, but results in an increased risk of death from all causes and stroke.
Summary: Trials of routine use of -blockers in patients undergoing
noncardiac surgery have reported conflicting results. The authors performed
a randomized controlled trial in 190 hospitals in 23 countries to investigate
the effects of perioperative -blockers. Initially, 9280 patients with, or at risk
of, atherosclerotic disease and undergoing noncardiac surgery were random-
ized to receive extended-release metoprolol succinate or placebo. Unfortu-
nately, it was determined that there were fraudulent data from six hospitals
in Iran (752 participants) and three hospitals in Columbia (195 partici-
pants). These patients were excluded from the data, leaving 8351 patients
from 190 hospitals in 23 countries for analysis.
There were 4174 persons randomized to receive metoprolol and 4177
to receive placebo. Medication was administered 2 to 4 hours before surgery
and continued for 30 days. Outcome adjudicators, data collectors, and
health care providers for the individual patients were masked to treatment
allocation. The primary end point was a composite end point of nonfatal
myocardial infarction, nonfatal cardiac arrest, and cardiovascular death.
Analysis was by intention to treat. The analysis included 8351 patients, and
8331 (99.8%) completed the 30-day follow-up.
In the metoprolol group, 244 (5.8%) reached the primary end point vs
290 (6.9%) in the placebo group (hazard ratio [HR], 0.84; 95% confidence
interval [CI], 0.70-0.99; P  .0399). Fewer patients in the metoprolol
group sustained myocardial infarction vs the placebo group (176 [4.2%] vs
239 [5.7%]; HR, 0.73; 95% CI, 0.60-0.89; P .0017). More overall deaths
occurred in the metoprolol group than in the placebo group (129 [3.1%] vs
97 [2.3%]; HR, 1.33; 95% CI, 1.03-1.74; P  .0317). More strokes
occurred in the metoprolol group than the placebo group (41 [1.0%] vs 19
[0.5%]; HR, 2.17; 95% CI, 1.26-3.74; P  .0053). Predetermined sub-
group analyses for region, whether on-site monitoring occurred, and based
on the presence of known atherosclerotic cardiovascular disease did not
show subgroup effects. Post hoc multivariable analysis indicated clinically
significant hypotension contributed to the risk for death and stroke.
Comment:The study has potentially huge implications but needs to be
interpreted with caution. Although it is routine to treat patients with
atherosclerotic risk factors undergoing high-risk surgery with perioperative
-blockers, -blockade was begun only 2 to 4 hours before surgery in this
study. The results may not apply to patients with more extended periods of
treatment with preoperative -blockers. The data indicate that under the
conditions of the trial, extended-release metoprolol can reduce the risk of
myocardial infarction. This, however, is at a cost of an increased risk of death,
stroke, and clinically significant hypotension. The authors also performed a
number of meta-analyses of trials of -blockers. Analysis of nine trials,
including Perioperative Ischemic Evaluation Study (POISE), in which at
least one patient had a fatal myocardial infarction, also indicated -blockers
reduced the risk of myocardial infarction and increased the risk of nonfatal
stroke (HR, 2.19; 95% CI, 1.26-3.78; P .005). The authors point out that
for every 1000 patients undergoing noncardiac surgery, and with similar risk
profiles to those in POISE, extended-release metoprolol can be expected to
prevent 15 myocardial infarctions and prevent seven patients from undergo-
ing new clinically significant atrial fibrillation. However, extended-release
metoprolol will also result in an excess of eight deaths and five additional
patients having a stroke, with 53 experiencing clinically significant hypoten-
sion and 42 experiencing clinically significant bradycardia.
Once again an accepted axiom of perioperative care appears to have
been refuted by a large randomized trial. Vascular surgeons may need to
reconsider the use of routine perioperative -blockade in their patients.
Major Lower Extremity Amputation after Multiple Revascularizations:
Was It Worth It?
Reed AB, Delvecchio C, Giglia JS. Ann Vasc Surg 2008;22:335-40.
Conclusions: The large majority of patients who undergo amputation
after multiple attempts at revascularization would still opt to do everything
possible to save the leg.Summary: Both lesion-specific and patient-specific outcomes are im-
portant in the assessment of treatments for lower extremity arterial occlusive
disease. In particular, lower extremity revascularization is often described as
lesion-centric, with excessive focus on treatment of the lesion and inade-
quate assessment of patient quality of life. The authors sought to investigate
patients’ perspectives of multiple procedures for limb salvage that eventually
cumulated in amajor lower extremity amputation. Patients who had undergone
below knee or above knee amputation after failed lower extremity revascular-
ization were surveyed by telephone by a vascular nurse. Patients were asked
about undergoingmultiple procedures for limb salvage, involvement in decision
making, functional status, use of a prosthesis, and independence. Patientswhose
amputations were performed for infection were excluded.
There were 78 patients who underwent an above or below knee
amputation after failed revascularization; of these, 46 (59%) were alive at 5
years, and 13 were lost to follow-up, leaving 33 available for inclusion in the
survey. These patients had a total of 142 lower extremity revascularizations
(median, 4 per patient), including 94 surgical bypasses and 48 percutaneous
interventions. According to the survey results, 85% of the amputees (28 of
33) would do everything to save the leg if faced with a similar scenario,
regardless of the number of procedures required. Thirty of 33 patients (91%)
resided at home, and 18 of 33 (54%) used a prosthesis.
Comment: The authors conclude patients are willing to undergo
multiple revascularizations in an attempt to salvage a limb even if the
eventual result is amputation. However, only survivors who appeared to be
doing reasonably well were available for participation in this survey, and
only 33 of the 78 patients who underwent above or below knee ampu-
tations after failed revascularization were surveyed. The attitudes of the
patients who were lost to follow-up or who did not survive are crucial to
the validity of the authors’ conclusion and limit the general applicability
of this study.
Characterization of the Inflammatory Cells in Ascending Thoracic
Aortic Aneurysms and in Patients with Marfan Syndrome, Familial
Thoracic Aortic Aneurysms, and Sporadic Aneurysms
He R, Guo D-C, SunW, et al. J Thoracic Cardiovasc Surg 2008;136:922-9.
Conclusion: Inflammatory cell infiltrates contribute to the pathogen-
esis of thoracic aortic aneurysm (TAA). Stimulation of T lymphocytes may
contribute to the initial immune response leading to this inflammatory
infiltrate.
Summary: The etiologies of abdominal aortic aneurysms (AAAs) and
TAAs are likely not the same. Although some TAAs are degenerative, as are
AAAs, significant numbers of TAAs affect a younger population in which the
primary pathology is a genetically influenced degeneration of the medial
layer of the arterial wall. Histologically, this is represented by loss of smooth
muscle cells, increased accumulation of proteoglycans, and diminished num-
bers of and fragmentation of elastic fibers. Such patients are known to have
an inflammatory infiltrate in the aortic wall. In this study the authors sought
to characterize this inflammatory infiltrate.
Full aortic segments in patients undergoing elective repair with Marfan
syndrome (n  5), familial thoracic aortic aneurysms (n  6), and thoracic
aortic aneurysms (n  9) were collected at the time of operative repair. The
study also used five control aortas that were obtained from patients who died
of a process unrelated to aortic dissection and who had no evidence of sepsis
at the time of death. The aortic samples were subjected to immunohisto-
chemistry staining using antibodies against markers of macrophages and
lymphocytes. Polymerase chain reaction analysis was used to quantify the
expression level of T-cell receptor -chain variable region gene. Mutations
in this gene lead to varied phenotypes associated with TAAs and thoracic
dissections.
Immunohistochemistry analysis demonstrated the adventitia and me-
dia from the aortas of patients with Marfan syndrome, familial TAA, as well
as sporadic cases of TAAs had increased numbers of T lymphocytes and
macrophages compared with the control aortas. There was an inverse
correlation with age with the number of T cells and macrophages in the
aortic media. Profiling of the T-cell receptors suggested a similar clonal
nature of T cells in the aortic wall, regardless of whether the patient had
sporadic aortic disease, Marfan syndrome, or familial TAA. More inflamma-
tory cells were present in the aortas of patients with genetic defects than in
patients with sporadic aneurysms.
Comment: The number of macrophages and inflammatory T lympho-
cytes in the aortic media of the samples used in this study negatively
correlated with the patient’s age. This raises the possibility that inflammatory
cells may contribute to disease progression and aortic expansion in patients
with TAAs. An alternative explanation is that the inflammatory infiltrate
correlate with aortic dilatation and parallel the dilatation and corresponding
pathologic changes but in themselves do not contribute to disease progres-
sion. However, no correlation existed between aortic diameter and the
number of inflammatory cells, implying that the inflammatory infiltrate is
not simply a result of the aortic dilatation and irritation of the tissues from
enlargement of the aorta. Clearly, the biologic activity of the macrophages
and T cells present in the aortic media of patients with TAAs needs to be
further characterized. The authors also point out that an immune-mediated
